Monday, March 28, 2022 Daily Archives

Intensified Mammalian Cell Culture: Harvest with a Single-Use Hermetic Centrifuge System

by

The production of increasingly higher cell densities has stressed the already limited solids-handling capabilities for traditional intermittent ejection centrifuge systems. By contrast, a single-use disc-stack centrifuge based on the solids-flow principle offers distinct advantages for cell culture harvesting. Such benefits include solids handling of high-density cell culture processes and elimination of the separation disruption and aerosol generation associated with the intermittent solids ejection. A single-use system also provides well-established benefits of disposable components — such as removal of steam- and…

March 28, 2022

Swiss CDMO expands drug product plant

by

ten23 health will add 1000 square meters at its site in Visp, Switzerland by expanding into an adjacent building. The contract development manufacturing organization (CDMO) acquired its Visp, canton of Valais, Switzerland manufacturing site from swissfillon last October. Now, the firm will add 1,000 square meters of clean room space to enlarge its cold storage and visual inspection capacity. “ten23 health needs to increase the supporting infrastructure in order to utilize our assets for sterile production in Visp,” a spokesperson…

March 28, 2022

Latent application: Moderna lauds mRNA manufacturing for herpes, HIV and beyond

by

Moderna says the flexibility and footprint of mRNA production can overcome scaling-up issues seen with current latent virus vaccines like GSK’s Shingrix. Moderna entered the ‘Big Pharma’ space in 2021 when its COVID-19 vaccine Spikevax became the second messenger RNA (mRNA) product to achieve commercial success. Last year, 807 million doses of the vaccine were sold, bringing in $17.7 billion for Moderna. For comparison, Moderna reported total sales in 2020 of $803 million and $60 million in 2019. Going forward,…

March 28, 2022

Wockhardt and Serum to construct plant in UK

by

Wockhardt and Serum Life Sciences UK have partnered to build a facility in Wrexham, Wales to manufacture various vaccines. Wockhardt, headquartered in Mumbai, India said the collaboration with Serum Life Sciences UK (a subsidiary of the Serum Institute of India) will deliver an additional 150 million doses of a wide range of vaccines through building a fill-finish facility in Wrexham, North Wales. “We are delighted to have formed a strategic partnership between Wockhardt and Serum Life Sciences. The collaboration will…

March 28, 2022